INTEGRATED MICROFLUIDIC PLATFORM FOR PROTEOMIC AND GENETIC EXOSOME DETECTION
In order to adapt treatment to the multicity of cancer types, cancer patient management has been revolutionized in the past decades by personalized medicine. As part of this strategy, liquid biopsy has emerged as a non-invasive ap...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
FG_WIT
AUTOMATED PROTOTYPE OF CANCER DETECTION FROM CTDNA
75K€
Cerrado
uQuantEV
Microfluidic EV Quantification for Point-of-Care CRC diagnos...
165K€
Cerrado
MoP-MiP
Molecular Programming for MicroRNA profiling
1M€
Cerrado
CANCER-ID
Cancer treatment and monitoring through identification of ci...
21M€
Cerrado
CTCPROTEOMIC
Single cell proteomics for studying circulating tumor cells...
200K€
Cerrado
PLEC2021-007892
Plataforma (Oncodeeplasm) para inmunoensayos optoplasmónicos...
336K€
Cerrado
Información proyecto IMPED
Duración del proyecto: 39 meses
Fecha Inicio: 2020-04-10
Fecha Fin: 2023-07-19
Líder del proyecto
INSTITUT CURIE
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
225K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
In order to adapt treatment to the multicity of cancer types, cancer patient management has been revolutionized in the past decades by personalized medicine. As part of this strategy, liquid biopsy has emerged as a non-invasive approach for personalized diagnostics and treatment. So far, this approach has focused on circulating tumor cells and circulating tumor DNA. However, extracellular vesicles termed exosomes, which are implicated in cellular communication and molecule transfer, have risen as promising biomarkers for earlier and more accurate detection. The IMPED project aims at developing a next-generation technology able to extract and analyse single exosomes or sub-groups of exosomes on both the proteomic and genomic level. This platform will offer beyond state-of-the-art information on the involvement of exosomes in cancer development. It has the potential to increase the precision of liquid biopsy analysis and provide clinically relevant insight for personalized cancer management. Toward this goal, the IMPED project will gather three technologies allowing low-cost extraction and analysis of exosomes from human plasma: (1) Continuous label-free extraction of exosomes from complex matrices (plasma) using thermophoresis (2) Proteomic profiling of single exosomes immobilized on a nanoarray with possibility of release (3) Droplet-based reverse transcriptase polymerase chain reaction (RT-PCR) of exosomes for RNA content analysis To our knowledge, this would be the first technology to couple intra- and extra-vesicle detection on a single/subpopulation exosome level within a single platform. The IMPED project is interdisciplinary, connecting physics, microfluidics and bioassay development for biomedical applications.